+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity



Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity



Journal of Autoimmunity 36(3-4): 201-209



The purpose of the study was to examine the potential of inhibition of cathepsin S as a treatment for autoimmune diseases. A highly selective cathepsin S inhibitor, CSI-75, was shown to upregulate levels of the cathepsin S substrate, invariant chain Lip10, in vitro as well as in vivo in C57Bl/6 mice after oral administration. Functional activity of the compound was shown by a reduction in the OVA-specific response of OVA-sensitized splenocytes from C57Bl/6 mice as well as from OVA-TCR transgenic mice (DO11.10). Since these studies revealed a selective suppression of the Th1 and Th17 cytokines causing a shift to Th2, CSI-75 was tested in the murine HC-gp39-immunization model. Indeed, CSI-75 specifically reduced the circulating HC-gp39-specific IgG2a in these mice indicating selective inhibition of the Th1 type of response in vivo. The importance of especially the Th1 and Th17 cell subsets in the pathology of autoimmune diseases, renders CatS inhibition a highly interesting potential therapeutic treatment of autoimmune diseases. Therefore, CSI-75 was tested in a murine model of multiple sclerosis (i.e. experimental autoimmune encephalomyelitis (EAE)) in a semi-therapeutic setting (ie. oral treatment after initial sensitization to antigen). Finally, in a murine model with features resembling rheumatoid arthritis (the collagen-induced arthritis (CIA) model), CSI-75 was tested in a therapeutic manner (after disease development). CSI-75 caused a significant reduction in disease score in both disease models, indicating a promising role for CatS inhibitors in the area of therapeutic treatments for autoimmune diseases.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 056546280

Download citation: RISBibTeXText

PMID: 21439785

DOI: 10.1016/j.jaut.2011.01.003


Related references

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis. Arthritis Research and Therapy 13(2): R68, 2011

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Molecular Cancer Therapeutics 11(3): 670-679, 2012

The novel acronycine derivative S23906-1 is orally active in therapeutic models of metastatic disease. Proceedings of the American Association for Cancer Research Annual Meeting 43: 159, 2002

In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. Journal of Pharmacology and Experimental Therapeutics 297(1): 280-290, 2001

Cilomilast: orally active selective phosphodiesterase-4 inhibitor for treatment of chronic obstructive pulmonary disease. Annals of PharmacoTherapy 40(10): 1822-1828, 2006

An orally active, inhibitor of cathepsin S inhibits human trans vivo DTH. Inflammation Research 52(Suppl. 2): S 102, 2003

Effects of ONO-5334, a novel orally-active inhibitor of cathepsin K, on bone metabolism. Bone 49(6): 1351-1356, 2011

A selective orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of inflammatory bowel disease bd. Gastroenterology 96(5 Part 2): A535, 1989

Differential cathepsin responses to inhibitor-induced feedback: E-64 and cystatin C elevate active cathepsin S and suppress active cathepsin L in breast cancer cells. International Journal of Biochemistry and Cell Biology 79: 199-208, 2016

Novel, orally active, proteasome inhibitor, delanzomib CEP-1877, ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. 2012

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE. International Immunopharmacology 12(1): 257-270, 2012

The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. European Journal of Immunology 38(1): 283-291, 2008

Anti-Il-12 MAb suppresses memory Th1 responses and is active in animal models of autoimmunity. Arthritis & Rheumatism 41(9 Suppl. ): S38, 1998

An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity. European Journal of Pharmacology 538(1-3): 168-174, 2006

TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. Molecular Cancer Therapeutics 11(3): 700-709, 2012